Unlike well described hereditary cancer risk syndromes such as BRCA1/2 [24–26], this is the first study to evaluate the prognosis of cancer in patients with germline pathogenic variants in PTEN (i.e. in individuals with PHTS). The gene discussed is PTEN; the disease is PTEN hamartoma tumor syndrome.